A nonparametric approach to practical identifiability of nonlinear mixed effects models
Tyler Cassidy, Stuart T. Johnston, Michael Plank, Imke Botha, Jennifer A. Flegg, Ryan J. Murphy, Sara Hamis · 2025
Read A nonparametric approach to practical identifiability of nonlinear mixed effects models by Tyler Cassidy, Stuart T. Johnston, Michael Plank, Imke Botha, Jennifer A. Flegg, Ryan J. Murphy, Sara Hamis (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/arxiv-2507-20288.txt.
Introduction
Tyler Cassidy and co-authors offer in 2025 a new check for a hard question in drug and virus modeling: can the data at hand pin down a model's traits? Modern work fits one model to many patients at once and learns how traits spread across the group. Older checks were built for one patient at a time.
Their method needs no set shape for how traits spread, which keeps it flexible. They show it on two known cases, one from drug dosing and one from virus growth. A sound check of this kind keeps teams from trusting trait values that the data never truly fixed.
Catalog record
| CREATOR | Tyler Cassidy, Stuart T. Johnston, Michael Plank, Imke Botha, Jennifer A. Flegg, Ryan J. Murphy, Sara Hamis |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 55 KB |
| VERSION | 1.0 |
| LICENSE | http://creativecommons.org/licenses/by/4.0/ |
| RIGHTS | CC BY |
| SOURCE | arXiv |
Source: https://arxiv.org/abs/2507-20288
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
A nonparametric approach to practical identifiability of nonlinear mixed effects models Tyler Cassidy, Stuart T. Johnston, Michael Plank, Imke Botha, Jennifer A. Flegg, Ryan J. Murphy, Sara Hamis Abstract 1 University of Leeds, Leeds, United Kingdom. 2 University of Melbourne, Melbourne, Australia 3 University of Canterbury, Christchurch, New Zealand 4 University of South Australia, Adelaide, Australia 5 Uppsala University, Uppsala, Sweden Correspondence to: [email protected] Abstract Mathematical modelling is a widely used approach to understand and interpret clinical trial data. This modelling typically involves fitting mechanistic mathematical models to data from individual trial participants. Despite the widespread adoption of this individual-based fitting, it is becoming increasingly common to take a hierarchical approach to parameter estimation, where modellers characterize the population parameter distributions, rather than considering each individual independently. This hierarchical parameter estimation is standard in pharmacometric modelling. However, many of the existing techniques for parameter identifiability do not immediately translate from the individual-based fitting to the hierarchical setting. Here, we propose a nonparametric approach to study practical identifiability within a hierarchical parameter estimation framework. We focus on the commonly used nonlinear mixed effects framework and investigate two well-studied examples from the pharmacometrics and viral dynamics literature to illustrate the potential utility of our approach. 1 Introduction Mathematical modelling has become an important approach to understand and interpret clinical trial data [ 66 , 51 , 31 , 69 ] . Typical mathematical models involve a number of unknown parameters, each representing a distinct biological mechanism, which are estimated by fitting the model to clinical trial data [ 29 , 43 , 74 , 18 ] . When considering the dynamics of distinct participants, this parameter estimation involves determining a set of model parameters that ensures that the model best represents the dynamics of each individual participant [ 11 , 7 , 52 , 76 ] . Consequently, individual trial participants are represented by a corresponding set of model parameters. However, for nonlinear mechanistic models commonly used to interpret clinical data [ 3 , 62 , 34 , 35 , 29 ] , it is possible that the model parameters are not uniquely determined by the available data for each participant. Consequently, there has been increased interest throughout the field of mathematical biology to understand the identifiability of mechanistic models [ 26 , 1 , 56 , 32 ] . Broadly speaking, identifiability analysis attempts to determines if the mapping from model parameterization to observable data is one-to-one. If this mapping is one-to-one in the idealized case where we observe every model output continuously, then the model is structurally identifiable. Structural identifiability is a property of the model structure and is independent of the experimental data available for parameterization [ 18 , 60 ] . Conversely, a mathematical model is practically identifiable if the model can be uniquely parameterized from available experimental data [ 37 , 60 , 68 , 46 ] . However, directly showing that available clinical data is sufficient to uniquely parameterize a mathematical model is difficult. Consequently, several analytic and computational approaches have been developed to study the identifiability of a mathematical model [ 21 , 60 , 44 , 65 , 12 , 2 , 59 , 72 ] . In general, these existing tools focus on determining if the observed individual-level dynamics are sufficient to constrain each individual parameterization. However, hierarchical parameter estimation approaches are becoming increasingly common in the mathematical modelling of clinical trial data. Rather than estimating a parameterisation for each individual participant, hierarchical approaches focus on determining multi-level parameter distributions. For example, nonlinear mixed effects (NLME) models are extensively used throughout the pharmacokinetics community, and the NLME framework is increasingly used in the development of mathematical models to understand clinical trial data [ 32 , 16 , 45 , 73 , 39 ] . These NLME models are designed to capture the inter-individual variability within a clinically relevant population [ 39 , 38 ] by simultaneously considering the totality of the individual-level dynamics to estimate the population-level parameter distributions. Essentially, the NLME framework leverages the entirety of the individual clinical data to constrain the population-level distributions. These population-level distributions then act as priors when determining the individual parameter sets for each participant [ 38 , 30 , 39 , 18 ] . Consequently, each individual participant represents a sample from the underlying population-level distribution. Many recent advances in parameter identifiability have are focused on individual-level dynamics and do not immediately extend to hierarchical modelling [ 60 , 59 ] . Consequently, there has been recent interest in extending existing identifiability techniques to a hierarchical modelling framework [ 67 , 33 ] . For example, Lavielle and Aarons, 2016 illustrated how models which are unidentifiable on the individual level may become identifiable at the population level, with examples drawn from pharmacokinetic modelling. In similar work, Duchesne et al., 2021 leveraged the parametric representation of population parameter distributions to facilitate model reduction in an in vitro model of erythropoiesis, while El Messaoudi et al., 2023 used a simulation-based approach to re-estimate the known parametric population distributions from simulated data. In each of these cases, the identifiability of the NLME model was assessed via estimates of the parametric representation of the population parameter distribution (for example, estimating the mean and variance of a lognormal distribution). This parametric perspective on identifiability of NLME models is a natural extension of the familiar definition of identifiability for non-hierarchical models [ 33 , 40 ] . However, this approach relies on a priori fixing a parametric representation of the population distribution and implicitly assumes that the individual participants can precisely determine the underlying patient population. Here, we propose a nonparametric approach to perform practical identifiability analysis of NLME models. Rather than determining if the individual samples precisely determine the population distribution, we wish to quantify if we can distinguish between the estimated population distributions. Informally, for two population parameter distributions that equally well describe the data, rather than asking if these two distributions are precisely equal, we instead wish to determine when they are different in some statistically significant way. We attempt to distinguish between these two distributions from the individual and population perspective. At the individual level, we use the Kolmogorov-Smirnov two sample test to determine if the individual estimates distinguish between the population parameter distributions. This approach identifies if the individual-level data is sufficient to distinguish between the underlying population parameter distributions. At the population level, we use the overlapping index of the two distributions [ 64 , 50 ] , which is related to the total variation difference between two probability measures, and measures the statistical difference between the distributions. We illustrate the proposed approach using a common example from pharmacology, the Friberg model of chemotherapy-induced neutropenia [ 25 ] , and a well-known example from mathematical biology, the standard viral dynamics model [ 51 ] . Both the Friberg and standard viral dynamics models have been extensively well-studied [ 75 , 46 , 24 ] and the sufficient conditions for the identifiability of both these models, when considering single-subject fits, are known. However, as shown by Lavielle, 2014 , the inter-individual variability present in clinical data may result in a model that is identifiable at the